Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics
Clinical Gastroenterology and Hepatology · 2025
DOI: 10.1016/j.cgh.2024.07.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Kenneth Ernest-Suarez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Rotavirus Vaccines, Inflammatory Bowel Diseases, Biological Products, Rotavirus Infections. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alberta Children's Hospital Research Institute.
Abstract (Originalsprache)
BACKGROUND & AIMS: Biologic therapies in the context of inflammatory bowel disease and pregnancy lead to improved maternal and fetal outcomes. Placental transfer results in detectable drug concentrations in infants. Rotavirus infection results in diarrheal related hospitalizations; however, the live oral vaccine is not currently recommended in biologic exposed infants. The aim of this study was to assess the effect of maternal biologic therapies on the infant immune system and safety of live rotavirus vaccination in biologic-exposed infants. METHODS: Biologic-exposed infants underwent standardized clinical assessments, drug concentration, and immune function testing (complete blood count, differential, immunoglobulin levels, extended B-cell and T-cell subset enumeration, Recent Thymic Emigrants, regulatory T-cell numbers, mitogen stimulation assays, and review of T-cell Receptor Excision Circles in the newborn screen). Rotavirus vaccine-specific adverse effects following immunizations up to 42 days post the last dose of the vaccine series were recorded. RESULTS: There were 57 infants born to 52 mothers with inflammatory bowel disease exposed to infliximab (n = 21), adalimumab (n = 19), vedolizumab (n = 10), and ustekinumab (n = 7) in the third trimester for a median of 39 weeks (interquartile range, 38-39 weeks) at delivery. Immunologic assessments validated for age were normal in all infants despite median infliximab concentrations of 6.1 ug/mL (range, 0.4-28.8 ug/mL), adalimumab concentrations of 1.7 ug/mL (range, 0.7-7.9 ug/mL), ustekinumab concentrations of 0.6 ug/mL (range, 0-1.1), and undetectable for vedolizumab at 10.7 weeks (interquartile range, 9.4-12.4) of age. The live oral rotavirus vaccine series was provided to 50 infants with the first dose given at a median of 13 weeks of age. No adverse effects following immunization were reported. CONCLUSION: Immune function testing was normal, and administration of live rotavirus vaccination appeared low-risk in biologic-exposed infants irrespective of circulating drug levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Section of Hematology/Immunology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
- Section of Infectious Diseases, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
- Public Health, Ontario and Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
- Department of Pediatrics, Dalhousie University and Canadian Center for Vaccinology, IWK Health Centre, Halifax, Nova Scotia, Canada.
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Förderung
- Alberta Children's Hospital Research Institute
Zitieren
APA
Ernest-Suarez, K., Murguía-Favela, L. E., Constantinescu, C., Fitzpatrick, T., Top, K. A., Hu, J., Jadavji, T., Leung, Y., Chan, M., Panaccione, R., & Seow, C. H. (2025). Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.07.007
Vancouver
Ernest-Suarez K, Murguía-Favela LE, Constantinescu C, Fitzpatrick T, Top KA, Hu J, et al. Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.07.007
BibTeX
@article{ErnestSuarez2025,
author = {Ernest-Suarez, Kenneth and Murguía-Favela, Luis E and Constantinescu, Cora and Fitzpatrick, Tiffany and Top, Karina A and Hu, Jia and Jadavji, Taj and Leung, Yvette and Chan, Melissa and Panaccione, Remo and Seow, Cynthia H},
title = {Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
doi = {10.1016/j.cgh.2024.07.007}
}
EUVIMED